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Glucocorticoid induced adrenal
insufficiency is common in steroid treated
glomerular diseases - proposed strategy for
screening and management
Alvin H. K. Karangizi1,2, May Al-Shaghana2, Sarah Logan2, Sherwin Criseno3, Rachel Webster4, Kristien Boelaert3,5,
Peter Hewins2 and Lorraine Harper1,2*
Abstract
Background: Glucocorticoids (GCs) are frequently used to treat glomerular diseases but are associated with
multiple adverse effects including hypothalamic-pituitary-adrenal axis inhibition that can lead to adrenal
insufficiency (AI) on withdrawal. There is no agreed GC tapering strategy to minimise this risk.
Methods: This is a single centre retrospective study, between 2013 to 2016, of patients with glomerular disease on
GC therapy for more than 3 months screened for GC induced AI with short synacthen stimulation tests (SSTs) done
prior to complete GC withdrawal. We investigated the prevalence of AI, predictors, choice of screening tool and
recovery.
Results: Biochemical evidence of GC induced AI was found in 57 (46.3%) patients. Total duration of GC did not
differ between those with and without AI (p = 0.711). Patients with GC induced AI had a significantly lower pre-
synacthen baseline cortisol as compared to patients without AI. A cut off pre-synacthen baseline cortisol of ≥223.5
nmol/l had a specificity of 100% for identifying individuals without biochemical AI. Patients with GC induced AI
took a mean of 8.7 ± 4.6 months (mean ± SD) to recover. Patients with persistent AI had a significantly lower index
post-synacthen cortisol measurement.
Conclusions: We demonstrate that biochemically proven GC induced AI is common in patients with glomerular
diseases, is not predicted by daily dose or duration and takes a considerable time to recover. The study supports
the use of morning basal cortisol testing as an appropriate means to avoid the need for SSTs in all patients and
should be performed in all patients prior to consideration of GC withdrawal after 3 months duration.
Keywords: Steroids, Medication, Screening, Renal disease, Cortisol, Short synacthen test, Adrenal insufficiency
Background
Glucocorticoids (GCs) are a widely used and effective
treatment for glomerular diseases such as lupus neph-
ritis, ANCA associated vasculitis and primary glomerular
diseases. GCs are effective in managing these conditions
but are associated with significant adverse effects such
as weight gain, diabetes mellitus, stomach ulceration,
gastrointestinal bleeding, infection and osteoporosis. To
minimise these risks, maintenance doses are generally
kept as low as possible and cessation is considered in
patients in stable remission [1].
GCs inhibit the hypothalamic-pituitary-adrenal (HPA)
axis through negative feedback. Chronic inhibition can
result in adrenal insufficiency (AI) which is unmasked on
withdrawal. This can be serious and potentially life threat-
ening as patients are unable to mount an adequate cortisol
stress response. The prevalence of AI after oral adminis-
tration of corticosteroids is common with estimates ran-
ging from 14 to 63% [2]. The dose and duration related
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threshold for developing AI is unclear. Studies show a re-
lationship between dose and duration of therapy, however
this has not been replicated in all studies and AI may
develop in those perceived to be at low risk with total
cumulative doses of Prednisolone less than 500 mg and
duration of therapy less than 4 weeks [2]. There are no
evidence-based guidelines to support current practice
on tapering of GCs [1]. Clinical practice in most cen-
tres is to gradually taper the dose of prednisolone with
the expectation that this will enable adrenal recovery.
To the contrary, a recent systematic review showed that
adrenal suppression can persist after withdrawal with
an absolute risk of 25.3% (CI 19.4 to 32.3%) at 6 months
post cessation [3].
Existing literature is conflicting regarding strategies to
mitigate this risk with some suggesting the need fora
low index of suspicion to test patients following with-
drawal and others advising switching to hydrocortisone
during tapering [1, 3]. In order to minimise the risk of
AI following steroid withdrawal, we adopted the ap-
proach of screening patients with a short synacthen
stimulation test (SST) prior to GC withdrawal. We have
now audited this practice to investigate its value in terms
of, identifying prevalence of biochemical AI, recovery
and screening tool choice. To the best of our knowledge,
no previous studies have specifically investigated GC
induced AI in glomerular disease.
Methods
Study design, settings and participants
This was a single-centre retrospective observational ser-
vice evaluation carried out in the Renal Department at
the Queen Elizabeth Hospital, Birmingham, UK. Patients
were identified using data log of all SSTs carried out by
our Kidney Assessment Team over a 3 year time period,
between September 2013 and September 2016. We in-
cluded all patients taking Prednsiolone, for longer than
3months, for glomerular disease who were screened for
AI prior to intended complete withdrawal from GCs.
We excluded patients on GCs for indications other than
glomerular disease, and patients who had SSTs per-
formed for indications other than planned GC with-
drawal This study received approval from the clinical
audit department at the Queen Elizabeth Hospital Bir-
mingham, UK in 2014 (Audit Code: CARMS-11451).
We collected data on patient age, sex, renal diagnosis,
date of diagnosis, date when GC commenced, highest re-
corded dose of Prednsiolone, use or non-use of Methyl-
prednisolone on induction, Prednsiolone dose at time of
SST, duration of Prednsiolone use, concurrent inhaled or
topical GC use, SST result, time to retest and time to
and result of subsequent SSTs where necessary. Data
was collected from our electronic medical record system
of test results and clinic letters.
Adrenal insufficiency definition and assay
Adrenal function was assessed by a Short Synacthen
stimulation Test (SST) performed between 08:30 am and
10:00 am after an overnight fast and 24 h Prednisolone
pause. Cortisol levels were measured before and 30min
after a bolus of 250 μg tetracosactide (Synacthen, Ciba--
Geigy) administered intramuscularly. Tetracosactide is a
synthesized polypeptide with an amino acid sequence
including 1 to 24 of the 1 to 39 chain of the naturally oc-
curring corticotropin. It has adrenocortical stimulatory
action similar to that of natural coticotropin [4]. It has
previously been established that the 30-min cortisol level
is used as the criterion to define adequate or inadequate
adrenal cortisol reserve, and is the standard by which
decisions are made to instigate (or terminate) gluco-
corticoid replacement [5]. The 30-min cortisol level pro-
vides reliable measure of adrenal function on the day of
the test and whether this is adequate or not [5–7]. All
synacthen tests were performed in the University Hospitals
Birmingham NHS foundation Trust by trained nurses and
the samples were analysed in the Biochemistry Laborator-
ies. During the initial data collection period, our laboratory
used the Roche cobas e602 Gen 1 competitive immunoassay
which had a 30min pass SST cut-off of cortisol ≥550
nmol/l derived using an in-house study of 100 healthy sub-
jects. In January 2016 there was a switch to a new assay,
Roche cobas e602 Gen 2 competitive immunoassay, due to
restandardisation with cortisol mass spectrometry method-
ology and data quality assurance schemes to align more
closely to reference material. The Gen 2 assay was shown
to have a − 18.25% negative bias and the 30min SST pass
cut-off was changed to ≥450 nmol/l to reflect this. Follow-
ing the change, an internal audit was performed to assess
the number of failed SSTs following the assay change.
There was no significant difference before or after. As of
mid-2017 (because of a shortage of Synacthen supply), the
endocrine department now recommends a morning 9
am basal cortisol as the baseline screening tool for
adrenal insufficiency with an adequate cortisol defined
as ≥350 nmol/l. Patients with a cortisol measurement
of < 350 nmol/l require a SST to confirm adrenal function.
Basal ACTH was not measured in this study.
Follow-up process
Patients who failed the SST were diagnosed with biochem-
ical AI and referred for review by an endocrine specialist
nurse. They were switched to hydrocortisone, a short-acting
synthetic glucocorticoid dosed at 10mg in the morning and
5mg in the evening to try to mimic endogenous cortisol
production. Patients were educated on sick day rules in-
cluding the need to double their doses in times of illness.
They were then retested at 6months, with hydrocortisone
withheld on the morning of the synacthen test. Patients
were retested at 6 monthly intervals until recovery.
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Statistical analysis
Data are presented as mean ± standard deviation for para-
metric variables and median (interquartile range) for
non-parametric variables. Categorical variables have been
expressed as counts (percentage). Between groups compar-
isons were performed using Mann Whitney U test, t-test
or Chi squared test as appropriate. A receiver-operating
characteristic (ROC) curve was performed to compute the
sensitivity and specificity of the pre-synacthen baseline
cortisol in predicting the outcome of the SST test. Stat-
istical analysis has been performed using GraphPad
Prism Version 5.00 (for Windows, 2007) and SPSS
version 22 (IBM Corp, 2013).
Results
Patient characteristics
One hundred and twenty three patients were included in
the study; the characteristics of the patients at the time
of SST are shown in Table 1. Primary glomerular dis-
eases represented in the study included IgA nephropa-
thy, IgA vasculitis, minimal change disease, idiopathic
membranous nephropathy, focal segmental glomerulo-
sclerosis and C3d glomerulonephritis. At the time of
SST testing, all patients were on Prednisolone doses of
5 mg or less. 80 (65%) of the patients had been on a dose
of 5 mg or less for at least 6 months before the test with
the remaining patients receiving higher doses during this
period. The duration of Prednisolone use was available
for 63 patients (51%) and ranged from 4 to 100months
(Table 1). Data on use or non-use of intravenous Meth-
ylprednisolone at induction was available for 93 patients
(75%) (Table 1). The initial daily dose of Prednisolone
was available for 79 patients (64%) (Table 1). 7 patients
were concurrently using GC inhalers. There was no
documented concurrent use of topical GCs.
Adrenal function
57 (46.3%) patients had an insufficient adrenal response
to the SST and were therefore diagnosed with biochem-
ical AI. There were no documented clinical episodes of
AI prior to the initial SST. The mean baseline cortisol of
patients who passed the SST was significantly higher
than those who failed with both assays (Table 2). There
was no significant difference in age, sex, total duration
of Prednisolone use, use of intravenous Methylpredniso-
lone at induction, initial Prednisolone dose, concurrent
GC inhaler use and degree of renal impairment between
the adrenal sufficient and insufficient patients (Table 2).
The outcome was also not influenced by whether or not
the patient had been on Prednisolone of 5mg or less for at
least 6months before the test. There was no significant
correlation between duration of Prednisolone and pre-
synacthen baseline cortisol (Fig. 1). Underlying glomerular
disease did not influence SST outcome (p = 0.193).
Switch to morning 9 am cortisol test
A ROC curve was performed using results of SSTs
performed with the Gen 2 assay (n = 27) (Fig. 2). A
pre-synacthen baseline cortisol (taken between 8:30 am
and 10:00) ≥223.5 nmol/l had a specificity of 100% for
passing the SST and a sensitivity of 72.73%. Values above
this threshold had a negative predictive value (baseline
result above this level indicates healthy individual) of
100% and a positive predictive value (baseline result below
this level indicates AI) of 84.2%. A pre-synacthen baseline
cortisol ≤119.5 nmol/l had a sensitivity of 100% for identi-
fying patients with biochemical AI. Utilising this lower
cut-off and the assay validated ≥350 nmol/l upper cut-off
would have resulted in 33.3% (n = 9) SSTs being avoided.
Follow-up
Thirty-eight (66.6%) of the 57 patients that failed the
SST have had follow-up re-testing. Of the 18 patients
that have not been re-tested, 4 are currently waiting for
the test, 1 patient died, 8 patients had disease relapse
and clinical indication to continue Prednisolone, 3 pa-
tients have opted to continue Prednisolone and 3 pa-
tients have been lost to follow-up. Of the 38 patients
that have been re-tested, 1 patient opted to go back on
Prednisolone and a further 4 had disease relapse and in-
dication to continue Prednisolone. Of the remaining 33
patients, 18 patients have recovered adrenal function
with a mean time of recovery of 8.7 ± 4.6 months and 15
patients have not recovered with latest testing at a mean
of 15.9 ± 9.2 months. Patients who have recovered from
Table 1 Baseline characteristics of all patients
Variable Result (n = 123)
Age (years) 51.9 years ±18.27
Sex (count) Male 63 (51.2%)
Female 60 (48.8%)
Renal diagnosis (count) ANCA-associated vasculitis 50 (35.7%)
Primary Glomerular disease 33 (26.8%)
Lupus nephritis 30 (24.4%)
Other 10 (13.0%)
Renal function (eGFR by
MDRDa equation)
66 (39–90)
Duration of Prednisolone use
(months) (data available for n = 63)
18 (9–35)
Induction with intravenous
methylprednisolone (count)
(data available for n = 93)
19 (20%)
Initial daily Prednisolone dose (mg)
(data available for n = 79)
50 (30–60)
Concurrent GC inhaler use (count) 7 (5.7%)
aeGFR by MDRD – Estimated Glomerular Filtration Rate by Modification of Diet
in Renal Disease Equation
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AI had a significantly higher post synacthen cortisol
concentration at their initial SST screen than patients
who have not recovered across both assays (Table 3).
There was no significant difference in age, duration of
prednisolone use, initial prednisolone dose and initial
pre synacthen baseline cortisol between the two groups.
The latest recovery was 23 months following discontinu-
ation of prednisolone.
Discussion
This study has demonstrated that GC induced AI is
common (46.3%) in patients with glomerular disease and
is present prior to complete withdrawal of Prednisolone.
To the best of our knowledge, this has not previously
been shown in a subgroup of patients on GCs for glom-
erular disease. Our results reflect similar prevalence of
AI to patients with rheumatoid arthritis receiving low
dose GCs [3]. Further analysis of this cohort has shown
that age, gender, underlying renal disease, duration of Pred-
nisolone use, use of intravenous Methylprednisolone at in-
duction, starting Prednisolone dose, concurrent GC inhaler
use and degree of renal impairment do not influence the
risk of AI. We have also shown that keeping patients on
maintenance Prednisolone doses of 5 mg or less for at
least 6 months does not lessen the risk. The literature is
conflicting over the effect of renal impairment on the
HPA axis [8, 9]. One study, with a limited number of
subjects, found comparable responses to ACTH be-
tween patients with renal impairment and controls
[10]. These results reinforce the need for a low index of
suspicion when withdrawing GCs, even in patients on
low doses.
Our study adds to the current understanding of AI by
identifying thresholds of baseline cortisol levels for
undertaking SSTs. Random cortisol measurements are
not a reliable assessment of the HPA axis due to the di-
urnal rhythm variation of secretion. Production however
peaks at around 08:00 to 09:00 am and previous studies
have shown a strong correlation between the basal
morning serum cortisol (08:00 to 09:00 am) and the peak
cortisol level after ACTH administration [11]. The mean
pre-synacthen baseline cortisol, taken between 8:30 am
and 10:00 am, in this study was significantly lower in pa-
tients who failed the SST. ROC analysis showed that a
pre-synacthen basal cortisol ≥223.5 nmol/l had a specifi-
city of 100% for identifying individuals with preserved
Table 2 Differences between patients who pass and fail SST
Variable SST Pass SST Fail P value
Age (years) 53 ± 2.3 51 ± 2.4 0.664
Duration of Prednisolone use (months) 17 (8–44) 22 (12.3–34.5) 0.711
Induction with intravenous Methylprednisolone (count) 11 (22%) 8 (19%) 0.686
Initial daily Prednisolone dose (milligrams) 60 (30–60) 40 (30–60) 0.315
GC inhaler use (count) 2 (3.0%) 5 (8.9%) 0.163
Prednisolone 5 mg or less for at least 6 months (count) 42 (64%) 38 (69%) 0.528
Renal function (eGFR by MDRD1 equation) 69 (40–90) 64 (37–89) 0.294
Pre synacthen baseline Cortisol (1st assay) (nmol/l) 380 ± 19 (n = 54) 200 ± 15 (n = 38) < 0.001
Pre synacthen baseline Cortisol (2nd assay) (nmol/l) 269 ± 31 (n = 11) 133 ± 20 (n = 18) < 0.001
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Fig. 1 Scatter graph of duration of prednisolone use plotted against pre-synacthen baseline cortisol result
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adrenal function and therefore supports the use of a
morning 9 am basal cortisol as an initial screen for AI
(validated cut off ≥350 nmol/l). In addition we found
that a basal cortisol < 119.5 mol/l adequately identified
patients with biochemical AI. We found that utilising
upper and lower limit cut offs would have avoided the
need for a SST in a third of patients. Indeed a previous
study found that the SST adds little value for a basal cor-
tisol of less than 100 nmol/l or more than 500 nmol/l
[12]. A worldwide shortage of Synatchen in 2014 led to
a substantial increase in price and avoidance of use may
provide a financial benefit [13].
A strength of our study is that we ensured that pa-
tients were off Prednisolone for 24 h prior to assessment
of adrenal function. All common corticosteroids except
Dexamethasone can cross-react with the assay to some
degree. The half-life for these agents is approximately
0.5–4.0 h so it is important that Prednisolone is paused
for at least 24 h prior to baseline cortisol measurements
[14, 15]. We switched patients identified with AI to
twice daily Hydrocortisone which has a shorter half-life
than Prednisolone as well as being more favourable on
bone mineral density [16]. Patients are also educated on
sick day rules and retested at 6 monthly intervals until
recovery.
Our study also adds to current understanding by evaluat-
ing duration and predictors of recovery. We have shown
that patients can take a considerable time to recover which
raises concerns over the safety of conventional practice of
unmonitored tapering. A higher initial post synacthen cor-
tisol concentration can predict earlier recovery and there-
fore could inform prognosis discussions with patients. The
latest recovery was 23months after discontinuation of
Prednisolone with not a single patient recovering more
than 2 years following Prednisolone discontinuation (three
patients with latest follow-up at 27, 33 and 36months re-
spectively). This finding suggests that there may be a co-
hort of patients that do not recover and have permanent
AI. A similar study done in patients with inflammatory
bowel disease found a longer time to recovery with a mean
of 3.1 ± 2.5 years (mean ± SD) however comparison be-
tween this study and our findings is limited by the small
0 20 40 60 80 100
0
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AUC = 0.9091 (95% CI 0.7911 - 1.027)
Criterion  223.5nmol/l
Specif icity = 100%
Sensitivity = 72.73%
PPV = 84.2%
NPV = 100%
100% - Specificity%
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S
Fig. 2 Pre-synacthen cortisol level as a predictor of SST outcome. Receiver-operating characteristic curve with true positive rate (sensitivity %)
plotted against false positive rate (100% - specificity%) for different cut-off levels
Table 3 Differences between patients who have recovered from AI and those who have not
Variable Recovered (n = 18) Not recovered (n = 15) P Value
Age (years) 53 ± 3.4 48 ± 4.8 0.451
Duration of Prednisolone use (months) 28 ± 25.7 25 ± 16 0.888
Initial Prednisolone dose (milligrams) 40 (IQR 30 to 60) 30 (IQR 25 to 55) 0.367
Index screen pre synacthen baseline cortisol 1st assay (nmol/l) 205 ± 30 (n = 14) 202 ± 31 (n = 9) 0.962
Index screen pre synacthen baseline cortisol 2nd assay (nmol/l) 208 ± 8.3 (n = 3) 134 ± 30 (n = 6) 0.148
Index screen post synacthen cortisol 1st assay (nmol/l) 439 ± 25 (n = 14) 343 ± 37 (n = 9) 0.034
Index screen post synacthen cortisol 2nd assay (nmol/l) 394 ± 24 (n = 3) 240 ± 38 (n = 6) 0.033
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sample sizes in both cohorts. The longer time to recovery
found in this study does however demonstrate delayed
recovery and supports the need to continue re-testing
patients with biochemical adrenal insufficiency even after
2 years of discontinuation [17].
One of the limitations of this study was its retrospect-
ive design, which led to incomplete access to data on
duration of Prednisolone and initial dose, including use
of intravenous glucocorticoids on induction. This design
may have also led to inaccurate figures on concurrent
use of alternate forms of GCs and selection bias due to
inability to capture data on patients lost to follow-up.
Patients were not instructed to withhold inhaled steroid
preparations on the day of the synacthen test which may
have suppressed the morning cortisol level, however,
from the available data; only 7 patients were using con-
current steroid inhalers. We found no association be-
tween duration of GC use and AI, however it must be
noted that all our patients had received at least 4 months
of GC therapy. The risk of AI has been noted to increase
with duration of therapy in many studies but there is
considerable variation reported. The relatively small
sample sizes in this study may have led to it being
underpowered to investigate the impact of initial daily
dose and duration of therapy. SST testing, although con-
venient, is not as accurate as testing the entire HPA axis
with alternate tests such as the overnight metyrapone
test or insulin tolerance test [18]. We used the standard
dose SST (250 μg synacthen) rather than the low dose
SST (1 μg synacthen). The later has shown a high inter-
method variability in dilution strategies which may result
in false positive rates impacting on test specificity [19].
There was a switch in assay towards the end of the data
collection window, which consequently resulted in
smaller sample sizes when analysing for differences in
cortisol levels and outcomes separately for each of
the assays. Despite this we still found significant rela-
tionships between a lower baseline cortisol in patients
who failed the SST and a higher post synacthen corti-
sol in the recovery group across both assays. An in
house audit found no significant difference in number
of failed SSTs following the assay change and it is
therefore unlikely that the change in assay had an ef-
fect on the results.
Conclusions
In summary, we have demonstrated that biochemical
GC induced AI is common in steroid treated glomerular
diseases. Initial Prednisolone dose and duration of use
did not predict the risk. 9 am basal cortisol is an appro-
priate first line screening tool and avoids the need for a
SST in some patients. Our proposed approach of screen-
ing patients, hydrocortisone replacement and education
aims to protect patients at risk of adrenal crisis.
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